Drug news

EU grants CE mark for Vizamyl for amyloid PET Imaging- GE HealthCare

Read time: 1 mins

Last updated:14th Sep 2014

Published:14th Sep 2014

Source: Pharmawand

GE Healthcare has announced that the amyloid PET radiotracer F-18 flutemetamol (Vizamyl) has been given the CE mark from the European Commission authorizing marketing of the device across Europa. Vizamyl now can be marketed as a radiopharmaceutical for amyloid PET imaging of neuritic plaque density in the evaluation of Alzheimer�s disease and other conditions associated with cognitive decline.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news